Literature DB >> 27441481

Interleukin 18 promotes myofibroblast activation of valvular interstitial cells.

Jingxin Zhou1, Jinfu Zhu1, Li Jiang2, Busheng Zhang3, Dan Zhu4, Yanhu Wu5.   

Abstract

BACKGROUND: Calcific aortic valve disease is the main heart valve disease in the elderly. Valvular interstitial cells (VICs) play an important role in the process of valve calcification. Interleukin 18 (IL-18) is expressed in stenosis aortic valves and is positively related with the clinical severity of aortic stenosis. However, the role of IL-18 in aortic valve calcification remains unclear. This study examined whether IL-18 promotes myofibroblast and/or osteoblast transdifferention of VICs. Porcine VICs were isolated and treated with recombinant porcine IL-18.
METHODS: Porcine VICs were cultured and treated with IL-18. Gene and protein expression of myofibroblastic and osteoblastic markers were tested and nuclear factor κB (NF-κB) phosphorylation was also analyzed. Alkaline phosphatase (ALP) staining and activity assay were also performed.
RESULTS: Our experiments demonstrated that IL-18 significantly enhanced alpha-smooth muscle actin (α-SMA) gene and protein expression. IL-18 treatment also promoted the expression of osteopontin (OPN) and runt-related transcription factor 2 (Runx2) mRNA, although OPN and Runx2 protein expressions were not changed. IL-18 could induce ALP activity in the presence of conditioning medium. We also demonstrated that IL-18 markedly enhanced NF-κB p65 phosphorylation in VICs.
CONCLUSIONS: Together these results suggest that IL-18 promotes the myofibroblast differentiation of VICs and accelerates calcification in the presence of conditioning medium via the NF-κB pathway.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Interleukin 18; Myofibroblast; Valvular heart disease; Valvular interstitial cells; α-Smooth muscle actin

Mesh:

Substances:

Year:  2016        PMID: 27441481     DOI: 10.1016/j.ijcard.2016.07.036

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  7 in total

Review 1.  Adaptive immune cells in calcific aortic valve disease.

Authors:  Michael A Raddatz; Meena S Madhur; W David Merryman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-05-03       Impact factor: 4.733

Review 2.  Innate and adaptive immunity in cardiovascular calcification.

Authors:  Livia S A Passos; Adrien Lupieri; Dakota Becker-Greene; Elena Aikawa
Journal:  Atherosclerosis       Date:  2020-02-28       Impact factor: 5.162

3.  Sex-dependent aortic valve pathology in patients with rheumatic heart disease.

Authors:  Feng Xiao; Rui Zheng; Di Yang; Kejiang Cao; Shijiang Zhang; Bingruo Wu; Yongfeng Shao; Bin Zhou
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

Review 4.  NLRP3 inflammasome: The rising star in cardiovascular diseases.

Authors:  Yidan Zheng; Li Xu; Nianguo Dong; Fei Li
Journal:  Front Cardiovasc Med       Date:  2022-09-20

5.  Comprehensive microRNA profiling reveals potential augmentation of the IL1 pathway in rheumatic heart valve disease.

Authors:  Qiyu Lu; Yi Sun; Yuyin Duan; Bin Li; Jianming Xia; Songhua Yu; Guimin Zhang
Journal:  BMC Cardiovasc Disord       Date:  2018-03-16       Impact factor: 2.298

6.  Interleukin-18 Amplifies Macrophage Polarization and Morphological Alteration, Leading to Excessive Angiogenesis.

Authors:  Takuro Kobori; Shinichi Hamasaki; Atsuhiro Kitaura; Yui Yamazaki; Takashi Nishinaka; Atsuko Niwa; Shinichi Nakao; Hidenori Wake; Shuji Mori; Tadashi Yoshino; Masahiro Nishibori; Hideo Takahashi
Journal:  Front Immunol       Date:  2018-03-06       Impact factor: 7.561

7.  IL-21 promotes osteoblastic differentiation of human valvular interstitial cells through the JAK3/STAT3 pathway.

Authors:  Zongtao Liu; Yixuan Wang; Jiawei Shi; Si Chen; Li Xu; Fei Li; Nianguo Dong
Journal:  Int J Med Sci       Date:  2020-10-20       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.